In vitro characterization of PrismaLung+: a novel ECCO 2 R device

摘要: Invasive mechanical ventilation is lifesaving in the setting of severe acute respiratory failure but can cause ventilation-induced lung injury. Advances extracorporeal CO2 removal (ECCO2R) technologies may facilitate more protective distress syndrome, and enable earlier weaning and/or avoid invasive entirely chronic obstructive pulmonary disease exacerbations. We evaluated vitro capacity novel PrismaLung+ ECCO2R device compared with two existing gas exchangers. The (surface area 0.8 m2, Baxter) was PrismaLung 0.35 m2, A.L.ONE 1.35 m2, Eurosets) devices, using a closed-loop bovine blood–perfused circuit. efficacy each measured at varying pCO2 inlet (pinCO2) levels (45, 60, 80 mmHg) blood flow rates (QB) 200–450 mL/min; devices were also tested QB 600 mL/min. amount removed by assessed measurement infused to maintain circuit equilibrium (CO2 infusion method) concentrations outlet (blood analysis method). performed similarly device, both demonstrating ~ 50% greater than device. 73 ± 4.0, 44 2.5, 72 1.9 mL/min, for PrismaLung+, PrismaLung, A.L.ONE, respectively, 300 mL/min pinCO2 45 mmHg. A Bland–Altman plot demonstrated that method comparable calculating removal. resistance across test as pressure drop, varied function rate, greatest lowest newly developed effectively performance tested, despite smaller membrane surface versus A.L.ONE. Clinical testing warranted further characterize its performance.